Archiv
Archiv anzeigen:
bis


Circulating Tumor DNA as a Prognostic Biomarker in Colon Cancer

David H. Ilson, MD, PhD reviewing Tie J et al. JAMA Oncol 2019 Oct 17, Burke HB and Kopetz S. JAMA Oncol 2019 Oct 17

Circulating tumor DNA after surgery or adjuvant chemotherapy was independently associated with excess risk for disease recurrence.


Intraductal Papillary Mucinous Carcinoma vs. Pancreatic Cancer: A Comparison

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Izumo W et al. Scand J Gastroenterol 2019 Nov 2

Prognosis is typically better with IPMC than with pancreatic cancer.


Gilteritinib for FLT3-Mutated Acute Myeloid Leukemia

Michael E. Williams, MD, ScM reviewing Perl AE et al. N Engl J Med 2019 Oct 31

The FLT3 inhibitor was superior to salvage chemotherapy in patients with relapsed or refractory disease.


Metformin for Sickle Cell Patients with Diabetes

Brady L. Stein, MD, MHS reviewing Badawy SM and Payne AB. Blood Adv 2019 Nov 1

Metformin use is associated with reductions in sickle-cell–related adverse events as well as in inpatient and emergency department visits.


Haploidentical Stem Cell Transplantation for Hematologic Cancers

Michael E. Williams, MD, ScM reviewing Gagelmann N et al. JAMA Oncol 2019 Oct 17

Mortality outcomes with haploidentical-donor SCT followed by cyclophosphamide were improved compared with mismatched-unrelated–donor SCT.


Managing Pregnancy in Women with Myeloproliferative Neoplasms

Brady L. Stein, MD, MHS reviewing Maze D et al. JAMA Netw Open 2019 Oct 2

Aspirin and interferon improved live birth rates among pregnant women with essential thrombocythemia or polycythemia vera.


Front-Line Immunotherapy for Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. Lancet 2019 Oct 4, Goetze TO. Lancet 2019 Oct 4

Adding durvalumab to chemotherapy significantly improved overall survival.


Nivolumab plus Ipilimumab for Advanced NSCLC: Updated Survival Results

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2019 Sep 28

Overall survival was improved versus chemotherapy in non–small-cell lung cancer patients, independent of their PD-L1 status or tumor mutational burden.


Rivaroxaban vs. Vitamin K Antagonists for Antiphospholipid Antibody Syndrome

Brady L. Stein, MD, MHS reviewing Ordi-Ros J et al. Ann Intern Med 2019 Oct 15, Wahl D and Dufrost V. Ann Intern Med 2019 Oct 15

Rivaroxaban failed to demonstrate noninferiority to VKAs in preventing recurrent thrombosis.


BRAF-Targeted Therapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

David H. Ilson, MD, PhD reviewing Kopetz S et al. N Engl J Med 2019 Sep 30

The combination of cetuximab and encorafenib, with or with or without binimetinib, significantly improved survival versus standard therapy.


Archiv
Seite von 85
Editorial Member Board Empfehlungen

Dr. med. Richard Herrmann

Prof. em. für Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Die Zahl der veröffentlichten Studien, die für die Betreuung unserer Tumorpatienten von Bedeutung sind, ist kaum mehr überschaubar. Hier hilft uns die Selektion des Teams von Journal Watch. Mit dieser neuen Serie soll eine weitere Auswahl getroffen werden. Diese ist, wie wohl auch die vorgenannte, nicht ohne Subjektivität. Für die Auswahl wichtig war mir ganz besonders die Praxisrelevanz.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.